3BNC117 and 10-1074 in HIV-infected Individuals - Full Text View

Purpose

This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.

Condition	Intervention	Phase
Human Immunodeficiency Virus (HIV)	Drug: 3BNC117 Drug: 10-1074 Other: Analytical treatment interruption Drug: Placebo	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator) Primary Purpose: Treatment
Official Title:	An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by Rockefeller University:

Primary Outcome Measures:

The number of participants with adverse events 1 week after 3BNC117 and 10-1074 infusions in all study groups. [ Time Frame: 1 week following each combination of 3BNC117 and 10-1074 infusion ]
Adverse events include: signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity
The decline in plasma HIV-1 RNA levels by a standard clinical assay in participants off ART enrolled in groups 1C and 3. [ Time Frame: 20-24 weeks ]
The percentage of participants who meet ART re-initiation criteria (plasma HIV-1 RNA ≥ 200 copies/ml and/or CD4 count < 350 cells/μl on two consecutive measurements) prior to 8 weeks after ART interruption in group 2. [ Time Frame: 30 weeks ]
Time to meeting ART re-initiation criteria (plasma HIV-1 RNA level ≥ 200 copies/ml, CD4+ T cell count < 350 cells/l in 2 consecutive measurements) following ART interruption in group 2. [ Time Frame: 30 weeks ]

Secondary Outcome Measures:

The number of participants with adverse events that occur during study follow up after 3BNC117 and 10-1074 infusions in all study groups. [ Time Frame: 20-30 weeks ]
Adverse events include signs, symptoms and laboratory abnormalities.
The serum level of 3BNC117 and 10-1074 at the time of viral rebound in all study groups. [ Time Frame: 20-30 weeks ]
Number of participants with induced anti-3BNC117 and anti-10-1074 antibodies. [ Time Frame: 20-30 weeks ]
Level of induced anti-3BNC117 and anti-10-1074 antibodies. [ Time Frame: 20-30 weeks ]
Change in number of CD4+ T cells/uL [ Time Frame: 20-30 weeks ]

Other Outcome Measures:

Changes in viral envelope sequences following 3BNC117 and 10-1074 infusions (groups 1C, 2-3) [ Time Frame: 20-30 weeks ]
Phylogenetic comparison of viruses grown from PBMCs collected from subjects while on ART to rebound viruses collected after treatment interruption (group 2). [ Time Frame: 20-30 weeks ]
Levels of cell-associated HIV-1 RNA and DNA before and after 3BNC117 and 10-1074 infusions in HIV-infected individuals. [ Time Frame: 20-30 weeks ]
Analysis of HIV-1 integration sites before and after 3BNC117 and 10-1074 infusions in HIV-infected individuals. [ Time Frame: 20-30 weeks ]
HIV-1 specific T and B immune responses following 3BNC117 and 10-1074 infusions (groups 1-3). [ Time Frame: 20-30 weeks ]
These will be measured by intracellular cytokine staining and by TZM.bl assays against a panel of viruses from multiple HIV clades.
Elimination half-life (t1/2) of 3BNC117 and 10-1074 [ Time Frame: 20-30 weeks ]
Clearance (CL/F) of 3BNC117 and 10-1074 [ Time Frame: 20-30 weeks ]
Volume of distribution (Vz/F) of 3BNC117 and 10-1074 [ Time Frame: 20-30 weeks ]
Area under the plasma concentration versus time curve (AUC) of 3BNC117 and 10-1074 [ Time Frame: 20-30 weeks ]
Decay Curves of 3BNC117 and 10-1074 [ Time Frame: 20-30 weeks ]


Estimated Enrollment:	37
Study Start Date:	June 2016
Estimated Study Completion Date:	June 2018
Estimated Primary Completion Date:	June 2018 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Group 1A HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.	Drug: 3BNC117 Intravenous infusion of 3BNC117 Other Name: Monoclonal Antibody Drug: 10-1074 Intravenous infusion of 10-1074 Other Name: Monoclonal Antibody Drug: Placebo Intravenous infusion of placebo (sterile saline) Other Name: Sterile Saline
Experimental: Group 1B HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.	Drug: 3BNC117 Intravenous infusion of 3BNC117 Other Name: Monoclonal Antibody Drug: 10-1074 Intravenous infusion of 10-1074 Other Name: Monoclonal Antibody Drug: Placebo Intravenous infusion of placebo (sterile saline) Other Name: Sterile Saline
Experimental: Group 1C HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.	Drug: 3BNC117 Intravenous infusion of 3BNC117 Other Name: Monoclonal Antibody Drug: 10-1074 Intravenous infusion of 10-1074 Other Name: Monoclonal Antibody
Experimental: Group 2 HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.	Drug: 3BNC117 Intravenous infusion of 3BNC117 Other Name: Monoclonal Antibody Drug: 10-1074 Intravenous infusion of 10-1074 Other Name: Monoclonal Antibody Other: Analytical treatment interruption Analytical treatment interruption Other Name: ART interruption
Experimental: Group 3 HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.	Drug: 3BNC117 Intravenous infusion of 3BNC117 Other Name: Monoclonal Antibody Drug: 10-1074 Intravenous infusion of 10-1074 Other Name: Monoclonal Antibody

Detailed Description:

The proposed study is a Phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-HIV broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals.

The study includes 5 study groups. Study participants will be administered one or three intravenous infusions of 3BNC117 and 10-1074, each mAb dosed at 10 or 30 mg/kg:

Single dose groups:

Group 1A (n=6) - HIV-infected individuals, on antiretroviral therapy (ART) with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one infusion of 10-1074, each dosed at 10 mg/kg (n=4), OR placebo (sterile saline; n=2), on day 0.

Group 1B (n=6) - HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg (n=4), OR placebo (sterile saline; n=2), on day 0.

Participants and investigators will be blinded to study assignment in groups 1A and 1B.

Group 1C (n=4) - HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.

Three doses groups:

Group 2 (n=15) - HIV-infected individuals, on ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 (week 3) and 42 (week 6). Participants enrolled in Group 2 will discontinue their antiretroviral (ART) regimen on day 2.

Group 3 (n=6) - HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 (week 2) and 28 (week 4).

Following 3BNC117 and 10-1074 infusions, study participants will return for safety assessments at multiple time points. Blood samples will be collected for safety testing at weeks 1, 2, and 4 following each mAb infusion, then bi-monthly or monthly until the end of study follow up.

Serum samples for PK (pharmacokinetic) measurements will be collected before the start of the first mAb infusion. Peak PK sampling for 3BNC117 will occur following the completion of the 3BNC117 infusion and prior to the start of the 10-1074 infusion. Peak PK sampling for 10-1074 will occur following the completion of the 10-1074 infusion. Additional samples for PK assessments will be collected at multiple time points during study follow up.

Samples will also be collected for measurement of HIV-1 plasma RNA levels before 3BNC117 and 10-1074 infusions (screen, pre-infusion and day 0), at all follow up visits in Groups 1A, 1B and 2, and weekly during the ATI period and at later time points in Group 2.

All participants will be followed for 24 weeks after the last 3BNC117 and 10-1074 infusions.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

All groups:

Age 18 to 65.
HIV-1 infection confirmed by two independent laboratory assays.
If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting intrauterine device (IUD), hormone-based contraceptive with condom) for the study duration.

Groups 1A and 1B:

HIV-infected volunteers on ART with HIV-1 plasma RNA levels < 20 copies/ml.
Current CD4 cell count > 300 cells/μl.

Groups 1C and 3:

HIV-infected volunteers off ART with detectable HIV-1 plasma RNA levels < 100,000 copies/ml by standard assays.
Current CD4 cell count > 300 cells/μl.

Group 2:

On antiretroviral therapy for a minimum of 24 months, with plasma HIV-1 RNA levels of < 50 copies/ml for at least 18 months, and < 20 copies/ml at screening. Note: a single viral load measurement > 50 but < 500 copies/ml during this time period is allowed.
Current CD4+ T cell counts > 500 cells/μl. CD4 cell count nadir > 200 cells/μl.
If on an NNRTI-based regimen willing to switch to a dolutegravir-based regimen for 4 weeks prior to discontinuing ART.

Exclusion Criteria:

Have a history of AIDS-defining illness within 3 year prior to enrollment.
History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months.
Any clinically significant acute or chronic medical condition (such as autoimmune diseases or coronary artery disease), other than HIV infection, that in the opinion of the investigator would preclude participation.
Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood.
History of resistance to 2 or more classes of antiretroviral medication or known resistance to dolutegravir in participants on non-nucleoside reverse-transcriptase inhibitors (NNRTI), who would switch regimen prior to ATI (Group 2).
Laboratory abnormalities in the parameters listed below:
Absolute neutrophil count ≤ 1,000 cells/l
Hemoglobin ≤ 10 gm/dL
Platelet count ≤ 100,000 cells/l
Alanine Aminotransferase (AST) ≥ 1.5 x ULN
Aspartate Aminotransferase (AST) ≥ 1.5 x ULN
Alkaline phosphatase ≥ 1.5 x ULN
Total bilirubin > 1.0 ULN
eGFR < 60 mL/min/1.73m2
Pregnancy or lactation;
Any vaccination within 14 days prior to 3BNC117 and 10-1074 administration;
Subjects with known hypersensitivity to any constituent of the investigational products;
Receipt of any therapeutic HIV vaccine or monoclonal antibody therapy of any kind in the past;
Participation in another clinical study of an investigational product currently or within past 12 weeks, or expected participation during this study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02825797

Contacts


Contact: Katelyn Bastert	800-782-2737	rucares@rockefeller.edu

Locations


United States, New York
The Rockefeller University	Recruiting
New York, New York, United States, 10065
Contact: Katelyn Bastert 800-782-2737 rucares@rockefeller.edu
Principal Investigator: Marina Caskey, MD

Sponsors and Collaborators

Rockefeller University

University Hospital of Cologne

Investigators


Principal Investigator:	Marina Caskey, MD	Rockefeller University

More Information


Responsible Party:	Rockefeller University
ClinicalTrials.gov Identifier:	NCT02825797 History of Changes
Other Study ID Numbers:	MCA-0906
Study First Received:	June 28, 2016
Last Updated:	December 23, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Keywords provided by Rockefeller University:


Broadly neutralizing antibody 3BNC117 10-1074

Additional relevant MeSH terms:


Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases	Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Antibodies Immunoglobulins Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 17, 2017